Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide

Area of Science:

• Immunology
• Biochemistry
• Pharmacology

Background:

• θ-defensins are macrocyclic peptides from Old World monkeys with antimicrobial and immunoregulatory functions.
• Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint destruction.

Purpose of the Study:

• To evaluate the therapeutic potential of rhesus θ-defensin 1 (RTD-1) in a rodent model of rheumatoid arthritis (RA).

Main Methods:

• Treatment of rats with established pristane-induced arthritis (PIA) using parenteral RTD-1.
• Assessment of joint disease progression, limb mobility, joint architecture, and levels of IL-1β and IL-6.
• Evaluation of RTD-1's effect on fibroblast-like synoviocyte (FLS) invasiveness and protease activity (ADAMs 10/17, MMPs, cathepsin K).

Main Results:

• RTD-1 rapidly suppressed joint disease, restored mobility, and preserved joint architecture in PIA rats.
• RTD-1 significantly reduced joint IL-1β levels and inhibited FLS IL-6 production.
• RTD-1 potently inhibited arthritogenic proteases including ADAMs 10/17, MMPs, and cathepsin K, and was non-toxic and non-immunogenic.

Conclusions:

• RTD-1 demonstrates significant efficacy in arresting and reversing joint disease in a rodent RA model.
• RTD-1's mechanism involves reducing inflammation and inhibiting key proteases involved in joint destruction.
• θ-defensins, absent in humans, represent a promising class of 'retroevolutionary' biologics for RA treatment.